Industry & Hardware
Rewrite Therapeutics
United Stateswww.fiercebiotech.com/biotech/intellia-rewrites-pipeline-expansion-200m-acquisition-uc-berkeley-dna-writing-startup
acquiredacquired
acquired
Stage
1
Investors
About
Rewrite Therapeutics is a UC Berkeley spinout developing CRISPR-guided DNA polymerization technology that enables genome editing without double-strand breaks, aiming to improve editing in non-dividing cell types.
Explore Rewrite Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.